* Benefits include proven risk reduction in CV and kidney events, and PAD benefits.
CV events = SUSTAIN-6: Results apply to Ozempic® 0.5 mg and 1 mg plus SOC
vs
placebo plus SOC in adults with T2D who have high CV risk, or established ASCVD;
kidney events (and all-cause death) = FLOW: Composite primary endpoint was
eGFR
decline (>50%), kidney failure, or death due to kidney-related or CV causes in adults with
T2D
and CKD;
PAD benefits = STRIDE: Results apply to Ozempic® 1 mg plus SOC vs placebo
plus
SOC in adults with T2D and PAD.
Reference: 1. Extensior® Professional Information, May 2026.
Reference: 2. Ozempic® Professional Information, May 2026.
Scheduling status: Scheduling status:
S4
| Name of medicine:
Extensior®
1.34 mg/ml solution for injection.
Qualitative and quantitative composition: Semaglutide 1.34 mg/ml.
Reg. No.: 57/21.13/0858.
For full prescribing information, refer to the Professional Information approved by
the
South African Health Products Regulatory Authority (SAHPRA).
Scheduling status:
S4
| Name of medicine:
Ozempic®.
Qualitative and quantitative composition: Semaglutide 1.34 mg/ml.
Reg. No.: 53/21.13/0167.
For full prescribing information, refer to the Professional Information approved by
the
South African Health Products Regulatory Authority (SAHPRA).
Novo Nordisk (Pty) Ltd, Reg. No.: 1959/000833/07.
90 Grayston Drive, Sandown, Sandton, 2031, Gauteng, South Africa. Tel: (011) 202 0500.
www.novonordisk.co.za.
ZA26SGDI00043. July 2026
